Barclays
UTHR icon

Barclays’s United Therapeutics UTHR Stock Holding History

Barclays’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-38,900
Closed -$3.69M – 6276
2020
Q1 		$3.69M Buy
38,900
+35,500
+1,044% +$3.37M ﹤0.01% 1727
2019
Q4 		$299K Sell
3,400
-4,000
-54% -$352K ﹤0.01% 4732
2019
Q3 		$590K Buy
7,400
+2,900
+64% +$234K ﹤0.01% 4111
2019
Q2 		$351K Sell
4,500
-29,300
-87% -$2.74M ﹤0.01% 4637
2019
Q1 		$3.97M Buy
33,800
+32,700
+2,973% +$3.81M ﹤0.01% 1859
2018
Q4 		$120K Sell
1,100
-1,100
-50% -$128K ﹤0.01% 4921
2018
Q3 		$281K Buy
2,200
+700
+47% +$86.6K ﹤0.01% 4729
2018
Q2 		$170K Sell
1,500
-800
-35% -$87.9K ﹤0.01% 4854
2018
Q1 		$258K Sell
2,300
-5,300
-70% -$673K ﹤0.01% 4600
2017
Q4 		$1.12M Buy
7,600
+2,300
+43% +$292K ﹤0.01% 3006
2017
Q3 		$621K Buy
5,300
+4,000
+308% +$511K ﹤0.01% 3413
2017
Q2 		$169K Sell
1,300
-61,300
-98% -$7.65M ﹤0.01% 4514
2017
Q1 		$8.47M Buy
62,600
+54,000
+628% +$8.18M 0.01% 982
2016
Q4 		$1.23M Buy
8,600
+500
+6% +$63.8K ﹤0.01% 2551
2016
Q3 		$956K Sell
8,100
-57,600
-88% -$6.92M ﹤0.01% 2667
2016
Q2 		$6.96M Buy
65,700
+12,300
+23% +$1.37M 0.01% 1080
2016
Q1 		$5.93M Buy
53,400
+50,900
+2,036% +$6.44M 0.01% 1061
2015
Q4 		$390K Sell
2,500
-1,100
-31% -$160K ﹤0.01% 3386
2015
Q3 		$472K Sell
3,600
-1,800
-33% -$289K ﹤0.01% 3390
2015
Q2 		$934K Sell
5,400
-14,400
-73% -$2.59M ﹤0.01% 2935
2015
Q1 		$3.41M Buy
19,800
+7,300
+58% +$1.11M ﹤0.01% 1866
2014
Q4 		$1.61M Sell
12,500
-5,600
-31% -$722K ﹤0.01% 2723
2014
Q3 		$2.32M Buy
18,100
+5,300
+41% +$546K ﹤0.01% 2529
2014
Q2 		$1.13M Buy
12,800
+10,300
+412% +$991K ﹤0.01% 3217
2014
Q1 		$235K Buy
2,500
+400
+19% +$40.9K ﹤0.01% 4630
2013
Q4 		$237K Sell
2,100
-4,900
-70% -$442K ﹤0.01% 4847
2013
Q3 		$546K Sell
7,000
-59,700
-90% -$4.36M ﹤0.01% 4017
2013
Q2 		$4.39M Buy
+66,700
New +$4.3M 0.01% 1728

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Barclays's UTHR Position: Q1 2026 in Review

Barclays reduced its United Therapeutics (UTHR) stake by 31% in Q1 2026, selling an estimated $13.9M and leaving 63,005 shares worth $37.4M. The position accounts for 0.01% of the portfolio, ranked #837.

Barclays first reported a position in UTHR in Q2 2013 and has held it in 52 quarters since. The position peaked at $47.3M in Q3 2025. 851 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

  • Barclays held 63,005 shares of United Therapeutics worth $37.4M as of Q1 2026.
  • Barclays sold 27,920 United Therapeutics shares in Q1 2026, an estimated $13.9M.
  • United Therapeutics made up 0.01% of Barclays's portfolio in Q1 2026, its #837 holding.
  • Barclays first reported a position in United Therapeutics in Q2 2013 and has held it in 52 quarters since.
  • Barclays's United Therapeutics position peaked at $47.3M in Q3 2025.
  • 851 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.